A Medtech Exec, Pharma Exec and Venture Capitalist Walk Onto a Stage and Talk Digital Health

Posted by Pete Masloski on Wed, Feb 13, 2019

Vijesh Unnikrishnan co-wrote this article with Pete Masloski.

This blog post was originally published on ZS's medtech blog, The Pacemaker

It’s not often that you get medtech, pharma and venture capital executives to sit on the same panel and participate with enthusiasm and excitement—unless the topic is digital health, where the cross-pollination of ideas and solutions across industry players is becoming more of a norm than an exception. At ZS’s recent Digital and Connected Health Summit, we were fortunate to host a panel of experts who engaged us in a lively discussion: Andy Atwell, executive director of new business development at Omron; Pankaj Dubey, senior director, U.S. commercial, at Abbvie; Divya Varshney, digital health lead at Baxter; and Megan Zweig, director of research at Rock Health. The panelists shared their excitement and optimism, and some examples of how they see life sciences companies adopting digital health solutions to solve patient needs and drive industry growth.


>
Read More

The Evolving Role of Medical Affairs: Four Trends to Watch

Posted by Sarah Jarvis on Wed, Jan 02, 2019

Sunil John co-wrote this post with Sarah Jarvis

Over the years, pharmaceutical companies’ medical affairs organizations have continued to grow not only in size but also in scope. Now, medical affairs groups are being leveraged as key strategic partners, and they’re being tapped for everything from generating real-world evidence to engaging patient advocacy groups to HEOR research. As a result, pharma companies are increasing their investment in medical affairs organizations: ZS’s 2018 Medical Affairs Outlook Report, which surveyed more than 100 medical affairs personnel from 45-plus companies,


>
Read More